Hematopoietic stem cell transplantation

Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo's Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations

Retrieved on: 
Saturday, June 16, 2018
Medicine, Clinical medicine, Chemistry, CD135, Quizartinib, Cancer treatments, Chemotherapy, Hematopoietic stem cell transplantation

The estimated survival probability at 1 year was 27 percent for patients who received quizartinib and 20 percent for patients who received salvage chemotherapy.

Key Points: 
  • The estimated survival probability at 1 year was 27 percent for patients who received quizartinib and 20 percent for patients who received salvage chemotherapy.
  • "In relapsed/refractory AML with FLT3-ITD mutations, these findings represent the first reported clinical data demonstrating that a single agent can significantly improve overall survival, suggesting that quizartinib could potentially help these patients live longer.
  • Additionally, in the study, a higher proportion of patients received a stem cell transplant in the quizartinib arm compared to the chemotherapy arm."
  • The primary objective of the study was to determine whether single agent quizartinib prolonged overall survival compared to salvage chemotherapy.

Bring light to someone who has been touched by the darkness of cancer on National Random Acts of Light Day, June 13

Retrieved on: 
Tuesday, June 12, 2018
Medicine, Stem cells, Clinical medicine, Anatomy, RTT, Hematology, Hematopoiesis, Hematopoietic stem cell transplantation, Surgical oncology, Cancer, Bone marrow

LTN is the perfect platform to showcase the progress being made in cancer arena along with the importance of supporting patients, one at a time.

Key Points: 
  • LTN is the perfect platform to showcase the progress being made in cancer arena along with the importance of supporting patients, one at a time.
  • "Random Acts of Light Daygives us the opportunity to create awareness and educate the public about the critical need to fund research to find cures for blood cancer patients, and ensure they have access to lifesaving treatments."
  • He underwentcountless tests, numerous bone marrow transplants and arigorous chemotherapy programbefore being cured when he was eight years old.
  • Bring light to someone you know who has been touched by cancer onNational Random Acts of Light Day.

Cellenkos™, Inc. Announces FDA Clearance of Investigational New Drug Application for CK0801 for Bone Marrow Failure Syndromes

Retrieved on: 
Monday, June 11, 2018
Biology, Medicine, Stem cells, Clinical medicine, Hematology, Biotechnology, Transplantation medicine, Cell biology, Bone marrow, Hematopoietic stem cell transplantation, Cell therapy, Fanconi anemia

The Phase I clinical trial of CK0801 will commence in the third quarter of 2018 at The University of Texas MD Anderson Cancer Center, Houston, Texas.

Key Points: 
  • The Phase I clinical trial of CK0801 will commence in the third quarter of 2018 at The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • "We are excited to launch the development of CK0801 as a novel cellular therapy approach to treat bone marrow dysfunction arising due to irregularities in the patient's immune system.
  • Bone marrow failure syndromerefers to the decreased production of one or more major hematopoietic lineages (white cells, red cells and platelets), which leads to diminished or absent hematopoietic precursors in the bone marrow.
  • Bone marrow failure remains an incurable disease except for those patients who are eligible to receive an allogeneic stem cell transplantation.

TempTraq® Detects Fevers Quicker than the Current Standard-of-Care Method

Retrieved on: 
Thursday, May 24, 2018
Medicine, Clinical medicine, 104th United States Congress, Data erasure, Health Insurance Portability and Accountability Act, Organ transplantation, Chemotherapy, Hematopoietic stem cell transplantation

To study this continuous, real-time method of body temperature measurement, UH tested the feasibility of monitoring body temperature for 17 patients specifically undergoing stem cell transplants and high dose chemotherapy.

Key Points: 
  • To study this continuous, real-time method of body temperature measurement, UH tested the feasibility of monitoring body temperature for 17 patients specifically undergoing stem cell transplants and high dose chemotherapy.
  • The TempTraq system is scalable and can support a single hospital or a multi-hospital/physician group healthcare system.
  • The company's TempTraq Connect HIPAA-compliant service supported by Google Healthcare Cloud Platform allows parents and caregivers to monitor body temperature from anywhere.
  • The TempTraq system is scalable and can support a single hospital or a multi-hospital/physician group healthcare system.

Moffitt Accredited For Stem Cell Transplant Programs

Retrieved on: 
Tuesday, May 22, 2018
Medicine, Biology, Stem cells, Clinical medicine, Cell therapy, Chemotherapy, Hematopoietic stem cell transplantation

PEMBROKE PINES, Fla., May 22, 2018 /PRNewswire-PRWeb/ -- After five rounds of chemotherapy in a seven-month period of 2017, leukemia patient Betty Zervoudakis required an allogenic stem cell transplant to survive.

Key Points: 
  • PEMBROKE PINES, Fla., May 22, 2018 /PRNewswire-PRWeb/ -- After five rounds of chemotherapy in a seven-month period of 2017, leukemia patient Betty Zervoudakis required an allogenic stem cell transplant to survive.
  • The facility has been accredited by The Foundation for the Accreditation of Cellular Therapy (FACT) for compliance with the FACT-JACIE International Standards for Hematopoietic Cellular Therapy.
  • To qualify, Moffitt had to meet or exceed cellular therapy standards, submit to a rigorous approval process, and pass an on-site inspection.
  • Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999.

Stem Cell Banking Market Worth 9.30 Billion USD by 2023

Retrieved on: 
Tuesday, May 15, 2018
Biology, Stem cells, Biotechnology, Cell biology, Stem cell, Stem-cell line, Amniotic stem cell bank, HSCT, Hematopoietic stem cell transplantation, Cord blood bank, Stem cell controversy

Factors such as increase in hematopoietic stem cell transplantation (HSCT) procedures, increasing investments in stem cell-based research, and growing awareness on the therapeutic potential of stem cells are driving the growth of the Stem Cell Banking Market.

Key Points: 
  • Factors such as increase in hematopoietic stem cell transplantation (HSCT) procedures, increasing investments in stem cell-based research, and growing awareness on the therapeutic potential of stem cells are driving the growth of the Stem Cell Banking Market.
  • Based on source, the Stem Cell Banking Market is segmented into placental, bone marrow-derived, adipose tissue-derived, human embryo-derived, dental pulp, and other stem cell sources.
  • The sample preservation & storage segment is expected to be the fastest growing segment during the forecast period owing to the growing adoption of stem cell banking services in major countries coupled with the rising number of stem cell banks across emerging countries, rising public awareness about the therapeutic applications of stem cells, increasing number of hematopoietic stem cell transplantations, increasing stem cell-based research, and high market penetration of stem cell banking services in major healthcare markets.
  • The expanding network of stem cell banking services, ongoing approval of stem cell lines for various disease treatment, recent technological advancements in the field of stem cell collection and preservation techniques, rising public-private investments for stem cell researches, growing number of stem cell transplantation procedures, and increasing public preference for private stem cell banking over public stem cell banks are driving the growth of the Stem Cell Banking Market in North America.